Evidence map›Paper›PMID 38822924›Full record

ArticleArchives of dermatological research2024

The effect of selinexor on prostaglandin synthesis in virus-positive Merkel cell carcinoma cell lines.

Deepika Narayanan, Brooke Bartley, Jennifer Landes, Stephen A Moore, Veda Kulkarni, Qin He, Rebecca Simonette, Hung Q Doan, Peter L Rady, Stephen K Tyring

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. EmergingFrontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Deepika NarayananDepartment of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.178, Houston, TX, 77070, USA.
Brooke BartleyDepartment of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.178, Houston, TX, 77070, USA.
Jennifer LandesDepartment of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.178, Houston, TX, 77070, USA.
Stephen A MooreDepartment of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.178, Houston, TX, 77070, USA.
Veda KulkarniDepartment of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.178, Houston, TX, 77070, USA.
Qin HeDepartment of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.178, Houston, TX, 77070, USA.
Rebecca SimonetteDepartment of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.178, Houston, TX, 77070, USA.
Hung Q DoanDepartment of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peter L RadyDepartment of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.178, Houston, TX, 77070, USA.
Stephen K TyringDepartment of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.178, Houston, TX, 77070, USA. Stephen.K.Tyring@uth.tmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with high rates of metastasis and mortality. In vitro studies suggest that selinexor (KPT-330), an inhibitor of exportin 1, may be a targeted therapeutic option for MCC. This selective inhibitor prevents the transport of oncogenic mRNA out of the nucleus. Of note, 80% of MCC tumors are integrated with Merkel cell polyomavirus (MCPyV), and virally encoded tumor-antigens, small T (sT) and large T (LT) mRNAs may require an exportin transporter to relocate to the cytoplasm and modulate host tumor-suppressing pathways. To explore selinexor as a targeted therapy for MCC, we examine its ability to inhibit LT and sT antigen expression in vitro and its impact on the prostaglandin synthesis pathway. Protein expression was determined through immunoblotting and quantified by densitometric analysis. Statistical significance was determined with t-test. Treatment of MCPyV-infected cell lines with selinexor resulted in a significant dose-dependent downregulation of key mediators of the prostaglandin synthesis pathway. Given the role of prostaglandin synthesis pathway in MCC, our findings suggest that selinexor, alone or in combination with immunotherapy, could be a promising treatment for MCPyV-infected MCC patients who are resistant to chemotherapy and immunotherapy.

Indexed as

Carcinoma, Merkel CellHydrazinesSkin NeoplasmsTriazolesAntigens, Viral, TumorCell Line, TumorExportin 1 ProteinHumansKaryopherinsMerkel cell polyomavirusProstaglandinsReceptors, Cytoplasmic and NuclearAntigens, Viral, TumorExportin 1 ProteinHydrazinesKaryopherinsProstaglandinsReceptors, Cytoplasmic and NuclearselinexorTriazolesMerkel cell carcinomaMerkel cell polyomavirusProstaglandinSelinexor

Identifiers

PMID38822924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.